维普期刊资源整合服务平台（V6.5）

90篇 您的检索式：作者名="Shaked S"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	The Caenorhabditis elegans par-5 gene encodes a 14-3-3 protein required for celluhr asymmetry in the early embryo显示文摘	Morton D G Shakes D C Nugent S	2002	Dev Biol2002，241，：	1
2	A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens显示文摘	Emmenegger U Man S Shaked Y	2004	Cancer Res2004，64，11：	1
3	The total time on test transform and the excess wealth stochastic order of distributions显示文摘	Kochar S C Li X Shaked M	2002	Advances in Applied Probability2002，34，：	1
4	The total time on test transform and the excess wealth stochastic orders of distributions显示文摘	S Kochar Li and M Shaked	2002	Advances in Application Probability2002，34，4：	1
5	High-Dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma显示文摘	Buckstein R Kerbel R S Shaked Y	2006	Clin Cancer Res2006，12，17：	1
6	Genetic heterogene- ity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of anti- angiogenesis显示文摘	Shaked Y Bertolini F Man S	2005	Cancer Cell2005，7，1：	1
7	The total time on test transform and the excess wealth stochastic order of distributions显示文摘	Kochar S C Li X Shaked M	2002	Advances in Applied Probability2002，34，：	1
8	The total time on test transform and the excess wealth stochastic order of distributions显示文摘	Kochar S C Li X Shaked M	2002	Advances in Probability2002，34，：	1
9	Relaxing Price Competition Through Product Differentiation 显示文摘	SHAKED A JOHN S	1982	Review of Economic Studies1982，49，：	1
10	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis;Implications for cellular surrogate marker analysis of antiangiogenesis显示文摘	Shaked Y Bertolini F Man S	2005	Cancer Cell2005，7，1：	1
11	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity显示文摘	Shaked Y Emmenegger U Man S	2005	Blood2005，106，9：	1
12	Genetic helerogeneity of the vasculogenic phenotype parallels angiogenesis:implications for cellular surrogate marker analysis of antiangiogenesis显示文摘	Shaked Y Bertolini F Man S		0，，：	1
13	Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models显示文摘	Daenen LG Shaked Y Man S	2009	Mol Cancer Ther2009，8，10：	1
14	MonopoLy and product quality显示文摘	Shaked M Rosen S	1982	Journal of Economic Theory1982，49，：	1
15	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis 显示文摘	Shaked Y Bertolini F Man S	2005	Cancer Cell2005，7，：	1
16	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity 显示文摘	SHAKED Y EMMENEGGER U MAN S	2005	Blood2005，106，9：	1
17	A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens显示文摘	Emmenegger U Man S Shaked Y	2004	Cancer Res2004，64，11：	1
18	Biliary tract complications afterorthotopic liver transplantation endoscopic approach to diagnosis andtherapy显示文摘	Jamidar P Shaked A	1995	Transplantation1995，60，：	1
19	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity 显示文摘	Shaked Y Emmenegger U Man S	2005	Blood2005，106，9：	1
20	Tumor dormancy and the angiogenic switch:possible implications of bone marrow-derived cells显示文摘	Shaked Y McAllister S Fainaru O	2014	Curr Pharm Des2014，20，30：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示